Please assess the completion status of the following clinical trial:

Trial Title: DEPORRA-CoProst: Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male patient over 18 years old.~* Patient scheduled for trans-urethral resection of prostate with:~  1. prostate specific antigen (PSA) blood level ≤ 4 ng/ml and age \> 80 years old~ 2. a suspected prostate cancer after a digital rectal examination (DRE) and a PSA blood level \> 50 ng/ml or an existing prostate cancer~* Patient affiliated to social security or beneficiary of such a regime.~Exclusion Criteria:~* Protected patient referred to in Articles L1121-6 to L1121-8 of the Code of Public Health

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluorescence assesment (Type: EXPERIMENTAL): All patients undergo a transurethral resection.~There are four different steps in the study:~* the first step: fresh prostatic tissue of 30 subjects will be use to asses the fluorescence signal and the entire chain,~* the second step: fresh prostatic tissue of 10 subjects will be used to asses the immunolabelling protocol,~* the third step: fresh prostatic tissue of 20 subjects will be used to asses the use of the FEMTO-ST institute medical device,~* the four step: the fresh prostatic tissue from the 10 subjects of the second step will be evaluated to verify the preservation of morphological structure with the use of the Light-CT scanner.

Based on this trial design, predict the completion outcome and termination type (if applicable).